The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Table 3 Compensatory changes in virus genotypes within 96 weeks of follow-up therapy.

Group	Patient ID	Protease mutations at start of therapy	Time of therapy failure	Time of 2nd genotype	Protease mutations after therapy failure
A	#1	L10FL, K20I, M36I, M46I, I50V, I54IV, L63P, L76V	Week 48	Week 144	L10F, V11I, I13V, K20R, V32I, L33F, M36I, M46I, I47V, I54M, L63P, A71V, G73S, I84V, L90M
	#2	L10V, M46I, I47V, L63P, A71V, L76V, V77I	Week 12	Week 48	L63P, V77I (therapy interruption)
	#4	L10V, K20RK, M36I, M46I, L63P, L76V, L90M	Week 12	Week 24	L10V, K20R, M36I, M46I, F53L, L63P, I84IV, L90M
	#22	L10I, L33F, M46L, I54V, L63P, A71I, L76V, V77I, V82A, L90M	Week 12	Week 48	L10I, L33F, M46L, F53L, I54V, L63P, A71T, G73S, V77I, V82A, L90M
B	#8	K20R, V32I, M46I, L76V, V82A	Week 48	Week 48	K20R, V32I, M36I, M46I, F53FL, L76V, V82A, L90LM
	#9	L10I, L24I, L33F, M46I, I54V, L63P, A71V, L76V, V82A	Week 12	Week 24	L10I, L24I, L33F, M46I, F53L, I54V, L63P, A71V, L76V, V82A, I84V
	#10	L10IV, K20I, M36I, M46I, I47V, F53L, L63P, A71V, G73 D, L76V, I84V, L90M	Week 12 compliance	Week 48	L10V, K20I, L33I, M36I, M46I, I47V, F53L, L63P, A71V, G73 D, L76V, I84V, L90M
	#27	L10I, M46I, I47V, L63P, A71V, L76V, L90M	Week 48	Week 48	L10I, M46I, I47V, L63P, A71V, L76V, I84V, L90M
C	#6	L10V, L33F, M46L, I54V, A71V, L63P, A71V, L76V, V82A	Week 12	Week 96	L10V, K20R, L33F, M36I, M46L, I54V, A71V, L76V, V82A
	#23	L10FIRV, L33F, I54MV, D60E, L63P, A71V, L76V, V82F	Week 12	Week 24	L10FIRV, L33F, I54MV, D60E, L63P, A71T/V, L76V, V82F

Compensatory changes in virus genotypes within 96 weeks of follow-up therapy. Patients with failing therapies within the 96 weeks received a second resistance testing. While L76V was still present in patients receiving L76V-selecting drugs, it was then absent in patients without these drugs (new detected mutation are underlined). Therapy failure in group B was noticeable associated with an additional establishment of the protease mutation L90 M.

ISSN: 1742-6405